Nexiclon XR™ (clonidine)
Go to Healthcare Provider Site

Save With The NEXICLON™ XR Patient Savings Card

Nexiclon XR savings card

Pay as little as
$5 for 30 days*

*Limitations apply. Reimbursement limited to $200 per month.

Patient Instructions:

Get a valid prescription for NEXICLON XR (clonidine) Extended-Release Tablets.
Ask your doctor if NEXICLON XR is right for you.

Register and download your NEXICLON XR Patient Savings Card Below

Fill your prescription by taking your prescription and the Card to your pharmacy.

Many eligible commercially insured patients may receive their prescription for as little as $5 for 30 days.*

*Program eligibility and restrictions apply. This offer is only valid for NEXICLON™ XR (clonidine) Extended-Release Tablets, manufactured for Athena Bioscience LLC. No substitutions permitted.

Fill in form below to receive a printable NEXICLON XR Extended-Release Tablets Patient Savings Card:
All fields are required.

Name(Required)
Email(Required)

Athena respects individual privacy and values the confidence of our customers. The information pertaining to you that we collect will be used in accordance with our Privacy Statement. By providing your email address, you agree and acknowledge that you would like to receive information from Athena related to NEXICLON XR and the NEXICLON XR Patient Savings Card, including site updates, education, and other NEXICLON XR products and services. If you later wish to opt out from receiving this information, you may click on the included opt-out link in future communications.

(Required)

The “Copay Savings Card” constitutes an offer subject to the below “Offer Terms, Conditions, and Patient Eligibility Criteria.” This offer is not insurance. Quantity limits may apply.

(Required)

OFFER TERMS, CONDITIONS, AND PATIENT ELIGIBILITY REQUIREMENTS

Each patient redeeming the Card acknowledges and agrees as follows:

  1. The offer constituted by the Card is only made to, and can only be accepted by, a patient who is 18 years of age or older, with a valid prescription for NEXICLON XR (clonidine) Extended-Release Tablets, manufactured for Athena Bioscience, LLC, when filled by a pharmacist at a participating pharmacy, and duly dispensed to the patient. No substitutions are permitted.
  2. Depending on applicable insurance coverage, eligible patients may receive their prescription for NEXICLON XR Extended-Release Tablets, manufactured for Athena Bioscience, LLC for $5.00 or less. Each patient accepting this offer should ask the fulfilling pharmacist to determine any applicable copay discount. Athena Bioscience, LLC makes no promise, guaranty, covenant, representation, warranty or other undertaking in regard to the actual savings, if any, that a patient may receive for NEXICLON XR, whether in consequence of the Card or otherwise.
  3. This offer is subject to a maximum limit of $200.00 per month, to be applied to any copay obligation that an eligible patient may have. Patient out-of-pocket expenses may vary.
  4. This offer is not valid for and may not be used by: patients enrolled in Medicare (including Part D), Medicaid, or other federal or state programs (including state pharmaceutical assistance programs, and for Puerto Rico, the Government Health Insurance Plan, formerly La Reforma de Salud, and for each any successor program); patients enrolled in private indemnity or HMO insurance plans or pharmacy benefit programs that in each instance reimburse the patient for the entire cost of a prescription drug; or patients who are Medicare-eligible and enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees.
  5. This offer is valid for those cash-paying patients not otherwise excluded by another provision of this offer.
  6. This offer is only good for the United States of America (including its States, territories and possessions, including Puerto Rico), at participating eligible retail, specialty, or mail-order pharmacies.
  7. This offer is void wherever prohibited by law or where it is taxed or restricted.
  8. The Card is limited to one per person and is not transferable. The selling, purchasing, trading, or counterfeiting of the Card is prohibited by law. The Card has no cash value and cannot be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified prescription.
  9. This offer neither constitutes, nor is a substitute for, health insurance. Each patient is responsible for applicable taxes, if any.
  10. Athena Bioscience, LLC may rescind, revoke, amend, modify or restate this offer at any time and from time to time without notice.
  11. Certain information related to or arising from your use of the Card will be shared with Athena Bioscience, LLC as the Card’s sponsor, together with Athena’s affiliates, including: the date your prescription is filled; the quantity of product dispensed to you by the pharmacist; and the amount of copay to be paid with the Card. Please see Athena’s Privacy Policy, athenabioscience.com/privacy-policy, for more information.
  12. At the time of acceptance, you are eligible for this offer, have read and understood it, and are bound by and agree to abide by its restrictions, terms, and conditions.

By using this offer, you and your pharmacist understand and agree to comply with these eligibility terms of use.

*Program eligibility and restrictions apply. This offer is only valid for NEXICLON XR (clonidine) Extended-Release Tablets, manufactured for Athena Bioscience LLC. No substitutions permitted. Void wherever prohibited by law, taxed, or restricted. Subject to the OFFER TERMS, CONDITIONS, AND PATIENT ELIGIBILITY REQUIREMENTS. Please see full prescribing information at www.nexiclonxr.com.

This field is for validation purposes and should be left unchanged.

Important Safety Information

NEXICLON™ XR (clonidine) Extended-Release Tablets is indicated in the treatment of hypertension. NEXICLON XR may be employed alone or concomitantly with other antihypertensive agents.

IMPORTANT SAFETY CONSIDERATIONS

Contraindications

NEXICLON XR should not be used in patients with known hypersensitivity to clonidine (rash, angioedema, hives).

Warnings and Precautions

Patients should not discontinue therapy without consulting a physician. Dose reduction should be performed gradually over a 2- to 4-day period to avoid withdrawal symptomatology. Rare instances of hypertensive encephalopathy, cerebrovascular accidents, and death have been reported after clonidine withdrawal.

Monitor carefully and titrate slowly in patients with severe coronary insufficiency, conduction disturbances, recent myocardial infarction, cerebrovascular disease, or chronic renal failure.

Patients who engage in potentially hazardous activities, such as operating machinery or driving, should be advised of a possible sedative effect of clonidine.

In perioperative use, NEXICLON XR may be administered up to 28 hours prior to surgery and resumed the following day.

Adverse Reactions

There is very little experience with NEXICLON XR in controlled trials. Based on this limited experience, the adverse event profile of NEXICLON XR appears similar to that of immediate release clonidine formulation. The most commonly expected adverse reactions are dry mouth, drowsiness, and dizziness.

Drug Interactions

No drug interaction studies have been conducted with NEXICLON XR; however the following have been reported with other oral formulations of clonidine:

  • Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates, or other sedating drugs.
  • Tricyclic antidepressants may reduce the hypotensive effect of clonidine, necessitating an increase in clonidine dose.
  • Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concomitantly with diltiazem or verapamil.

Use in Specific Populations

  • Pregnancy Category C. Clonidine is secreted in human milk.
  • Safety and effectiveness in pediatric patients have not been established.
  • Dose may need adjustment in patients with renal impairment.
  • Elderly patients may benefit from a lower initial dose.

Please see Full Prescribing Information for additional product information.

You are encouraged to report negative side effects of prescription drugs to Athena Bioscience, LLC at 1-833-874-2664 or to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.